Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh (950210) Price & Analysis

― Followers

950210 Stock Chart & Stats

₩5610.00

₩360.00(6.86%)

Jul 27, 2026

―

Day’s Range― - ―

52-Week Range₩4,945.00 - ₩15,900.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)67.47K

Market Cap

₩315.50B

Enterprise ValueN/A

Total Cash (Recent Filing)₩65.89B

Total Debt (Recent Filing)₩85.94B

Price to Earnings (P/E)―

Beta-0.07

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-957.25

Shares Outstanding60,096,153

10 Day Avg. Volume60,553

30 Day Avg. Volume67,472

Financial Highlights & Ratios

PEG Ratio-0.24

Price to Book (P/B)2.16

Price to Sales (P/S)61.73

P/FCF Ratio-9.30

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

950210 FAQ

What was Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s price range in the past 12 months?

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh lowest stock price was ₩4945.00 and its highest was ₩15900.00 in the past 12 months.

What is Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s market cap?

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s market cap is ₩315.50B.

When is Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s earnings last quarter?

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh released its earnings results on May 29, 2026. The company reported -₩350.038 earnings per share for the quarter, missing the consensus estimate of N/A by -₩350.038.

Is Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh overvalued?

According to Wall Street analysts Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh pay dividends?

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh does not currently pay dividends.

What is Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s EPS estimate?

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh have?

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has 60,096,153 shares outstanding.

What happened to Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s price movement after its last earnings report?

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh reported an EPS of -₩350.038 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.532%.

Which hedge fund is a major shareholder of Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh?

Currently, no hedge funds are holding shares in KR:950210

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh

Established in 2015 and based in Singapore, Prestige BioPharma Limited operates as a biopharmaceutical enterprise. The company's activities encompass the research, development, and commercialization of biosimilars and novel antibody therapeutics, primarily targeting the Asia Pacific market. A significant focus for Prestige BioPharma is the creation of antibody-based treatments for critical conditions such as solid tumors, pancreatic cancer, breast cancer, gastric cancer, and arthritis. Furthermore, the firm is also advancing the development of vaccines for the COVID-19 virus.